StockNews.com initiated coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a research report sent to investors on Sunday morning. The brokerage issued a sell rating on the stock.
Bio-Path Stock Down 0.0 %
BPTH stock opened at $0.80 on Friday. Bio-Path has a 1 year low of $0.61 and a 1 year high of $12.37. The company has a fifty day simple moving average of $0.96 and a 200 day simple moving average of $1.49.
Institutional Trading of Bio-Path
An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC bought a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 5.74% of the company’s stock.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
See Also
- Five stocks we like better than Bio-Path
- How to Use the MarketBeat Dividend Calculator
- Cerence Up 155% in 2 Days: SoundHound AI’s Fierce Competitor
- Find and Profitably Trade Stocks at 52-Week Lows
- Why Warren Buffett Is Selling: A Look at His Latest Market Moves
- Canada Bond Market Holiday: How to Invest and Trade
- Why Amazon Shares May Never Trade Below $200 Again
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
